On July 21, 2025, DSS, Inc. announced the successful execution of a Debt Conversion Agreement with Impact Biomedical Inc. This agreement involves the conversion of all outstanding debt owed by Impact, originally amounting to $12 million under a revolving promissory note, into 31,939,778 shares of Impact's common stock. This strategic move effectively settles the debt, including any additional financial or operational support extended by DSS or its affiliates, marking a significant step in DSS's financial strategy. The shares, valued at $0.001 per share, now constitute full and final satisfaction of all amounts owed, showcasing DSS's commitment to innovative financial solutions.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。